Yohanan Binoy, George Binsah
Department of Hematology/Oncology, The University of Texas Health Science Center at Houston, Houston, TX, USA.
Clin Med Insights Oncol. 2022 Dec 4;16:11795549221139357. doi: 10.1177/11795549221139357. eCollection 2022.
Despite the major advancements in the management of chronic phase (CP) chronic myeloid leukemia (CML), blast crisis (BC) remains a major therapeutic challenge. BC can be myeloid, lymphoid, or mixed lineage with myeloid BC being the most common type. BC in CML is mediated by aberrant tyrosine kinase activity of the fusion protein. The introduction of tyrosine kinase inhibitor (TKI) has been a gamechanger in the treatment of CML and there has been a significant reduction in the incidence of BC. The main treatment goal in BC is to achieve a second CP and consolidate that with an allogeneic stem cell transplantation (SCT) in eligible patients. The outcomes in BC remain dismal even in the current era. In this review, we provide an overview of the biology and current therapeutic approach in myeloid BC.
尽管在慢性期（CP）慢性髓性白血病（CML）的管理方面取得了重大进展，但急变期（BC）仍然是一个主要的治疗挑战。BC可以是髓系、淋系或混合谱系，其中髓系BC是最常见的类型。CML中的BC由融合蛋白异常的酪氨酸激酶活性介导。酪氨酸激酶抑制剂（TKI）的引入是CML治疗的一个重大变革，BC的发生率已显著降低。BC的主要治疗目标是实现第二次CP，并在符合条件的患者中通过异基因干细胞移植（SCT）进行巩固。即使在当前时代，BC的治疗结果仍然不佳。在本综述中，我们概述了髓系BC的生物学特性和当前的治疗方法。
